Please login to the form below

Not currently logged in
Email:
Password:

Duaklir

This page shows the latest Duaklir news and features for those working in and with pharma, biotech and healthcare.

Circassia exits allergy R&D after placebo effect strikes again

Circassia exits allergy R&D after placebo effect strikes again

Circassia also recently formed a partnership with AstraZeneca (AZ) for the development and commercialisation of two chronic obstructive pulmonary disease (COPD) medicines - Tudorza (aclidinium bromide) and Duaklir (aclidinium bromide/formoterol) in

Latest news

More from news
Approximately 3 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Deal Watch March 2017 Deal Watch March 2017

    AstraZeneca will complete the development of Duaklir (for which Circassia will contribute $462.5m) and will manufacture and supply the products. ... 250. AstraZeneca. Circassia Pharmaceuticals. Strategic collaboration. Tudorza (marketed) and Duaklir

  • Deal Watch table for November 2014 Deal Watch table for November 2014

    Eklira and Duaklir. Business unit acquisition. 3, 075. Pfizer / Merck KGaA.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics